Adipose Y5R mRNA is higher in obese than non-obese humans and is correlated with obesity parameters 
Introduction
Obesity is an adverse medical condition leading to a significant increase in health problems worldwide. 1 Obesity is associated with the growth of adipose tissue caused by an excess fat accumulation in adipocytes. 2 Excess adiposity is the result of adipocyte hypertrophy and/or hyperplasia. 2 There are two types of white adipose tissue depots including subcutaneous and visceral adipose tissues. 3 Subcutaneous fat is located at the hypodermis fat depot throughout the body. Visceral fat is located in the intra-abdominal compartment, including mesenteric, omental, retroperitoneal, perirenal and perigonadal regions. 3 Free fatty acids and adipokines secreted from visceral fat directly drain to the liver via the portal vein, while secretions of subcutaneous fat are transported through systemic veins. 3 
Impact statement
Obesity, defined as excess fat accumulation, has been increasingly diagnosed worldwide causing adverse health consequences. The novel findings of this study were that Y5R mRNA expression in both subcutaneous and visceral fat was higher in obese than non-obese subjects. Furthermore, Y5R only in visceral fat, not subcutaneous fat, was positively correlated with visceral Y1R and obesity parameters but it was negatively correlated with the QUICKI. Moreover, we found that Y1R expression was highest followed by Y5R and Y2R, respectively, in both subcutaneous and visceral fat. Our results suggested that Y5R in visceral fat was associated with increased obesity and decreased insulin sensitivity. Y1R and Y5R might be the dominant receptors that mediate the effect of NPY-induced fat accumulation in both subcutaneous and visceral adipose tissues. Y1R and Y5R in visceral adipose tissue might be targets of drug development in prevention or treatment of obesity.
Obesity is regulated by peripheral and central signals. One of the peripheral signals, leptin, decreases expression of orexigenic neuropeptides (neuropeptide Y (NPY)/ agouti-related peptide), but increases expression of anorexigenic neuropeptides (pro-opiomelanocortin/cocaine-and amphetamine-regulated transcript) in the brain, resulting in decreased food intake. 4 One of the factors regulating obesity is the 36-amino acid NPY. 4 NPY plays a central role in appetite stimulation 4 and has a peripheral action on fat proliferation 5, 6 and differentiation 5 in rodents. Furthermore, it has been shown that NPY treatment decreased glycerol release in human subcutaneous adipocytes suggestive of its anti-lipolytic effect. 7 NPY binds with the Y receptor, which is a G-protein coupled receptor. 8 Seven subtypes of the Y receptor, Y1 receptor (Y1R)-Y7 receptor (Y7R), have been discovered. 9, 10 Among these receptors, Y1R-Y5R are functionally expressed in humans.
11 Y1R, Y2R, and Y5R are abundantly expressed in the brain 12, 13 and play a major role in feeding regulation.
14 Moreover, Y1R, 13 Y2R, 5 and Y5R 13 are also found in the periphery, such as adipose tissue. Y5R is the gene of interest because it is expressed in humans in the central nervous system and in peripheral adipose tissue and is involved in regulation of appetite and obesity. 8 A previous study showed that treatment of Y5R antagonist inhibited cumulative food consumption in a fasting-induced feeding model in rats. 15 Furthermore, the central blockage of Y5R function decreased body weight, fat pads, and average adipocyte area of high-energy diet-induced obese rats. 16 However, a comparison of Y5R mRNA expression in subcutaneous and visceral fat between obese and non-obese subjects has not been studied. This study aimed to: (1) compare Y5R mRNA and morphology of adipocytes between obese and non-obese subjects and between subcutaneous and visceral adipose tissues, (2) compare expressions of NPY, Y1R, Y2R, and Y5R mRNA in subcutaneous and visceral adipose tissues, and (3) determine correlations between Y5R mRNA or adipocyte parameters with serum NPY levels, Y1R, Y2R, and clinical characteristics. Determination of differential NPY and Y receptor expressions in different types of adipose tissues may provide information regarding which receptor subtypes should be targeted in effective management of obesity. 17 Thirty-five female subjects (20 obese, 13 non-obese, and 2 overweight) were recruited from patients undergoing abdominal surgery. Overweight subjects were included only for correlation analysis. The exclusions criteria included participants who had endocrine therapy (for instance, steroids, hormone replacement therapy, and thyroxine), pregnancy, lactation, traumatic operations, malignant diseases, endocrine diseases, and severe abdominal inflammation. Male participants could not be recruited in this study, since most of the male patients undergoing open abdominal surgery had emergency conditions or cancer. In previous studies, visceral adipose tissue collected from open abdominal surgery was obtained only in female. 13 Menstrual phase of the patients could not be controlled because most of them had myoma uteri presenting with irregular menstruation.
Material and methods

Subjects
Demographic details and anthropometric measurements
Data on age, BMI, body weight, and waist and hip circumferences were collected. Waist circumference was measured at umbilicus level with silent breathing in the standing position. Hip circumference was measured in the standing position at inter-trochanteric girth. 18 Tissue and blood collection Blood samples were collected after 8 h of fasting before operations. During the operations, four to five pieces of 0.5 cm of abdominal subcutaneous and omental (visceral) adipose tissues from each patient were collected. Collected adipose tissue was snap-frozen immediately in liquid nitrogen and kept at À70 C until analysis.
Analysis of NPY, Y1R, Y2R, and Y5R mRNA expressions in adipose tissue NPY, Y1R, and Y2R mRNA expressions were quantified as described previously. 19, 20 Y5R mRNA was also quantified by the same technique. Briefly, total RNA was extracted by the TRIzol V R reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Complementary DNA (cDNA) was synthesized by reverse transcription of 1 mg of total RNA by the iScript cDNA Synthesis Kit (Bio-RAD, Hercules, CA). Real-time polymerase chain reaction (RT-PCR) was carried out with the reagents and protocol obtained from the VeriQuest SYBR Green qPCR Master Mix (Affymetrix, Santa Clara, CA). The reference gene was low-density lipoprotein receptor-related protein 10 (LRP10) since it was found to be the most stably expressed in adipose tissue of humans. 21 The sequences of the primers were designed and blasted to check primer specificity by the authors using nucleotide sequences published in PubMed database ( Table 1 ). The processes of PCR amplification included (1) 95 C for 10 min for Taq DNA polymerase activation, (2) 95 C for 15 s for 40 cycles for DNA denaturing, (3) 57 C for 60 s for annealing, and (4) 72 C for 30 s for extension. For every RT-PCR reaction, a negative control was performed by no template control and positive controls were performed by using human brain and placenta tissues. A comparative procedure of quantification was calculated by the 2 ÀDCT method.
Adipocyte morphometry
Histological staining was performed by using hematoxylin and eosin (H&E) stain to measure adipocyte morphometry. Briefly, abdominal subcutaneous and visceral adipose tissues from each patient were embedded in paraffin. Paraffin blocks were then sectioned at 20 mm thickness and paraffin slices were floated in a 40 C water bath and mounted on hydrophilic surface Twin-Mark microscope slides (Citotest Labware Manufacturing, Jiangsu, China). The sections were dried at room temperature and were kept at À70 C until staining. Adipocyte morphometry measurement was done by AxioVision V R software Release 4.8.2 (Carl Zeiss AG, Oberkochen, Germany) by drawing a line overlaying the outline of the adipocyte. Width is the shortest diameter of the adipocyte, whereas height is the longest diameter of the adipocyte.
Analysis of serum NPY levels
Analysis of serum NPY levels was as described previously. 19 Briefly, levels of serum NPY were assayed by a commercial enzyme immunoassay kit (Phoenix Pharmaceuticals, Burlingame, CA). The minimum measureable concentration of NPY levels was 0.14 ng/mL and range of NPY measurement was 0-100 ng/mL. The intraassay coefficient of variance of NPY was 10.1%.
Assessment of the quantitative insulin sensitivity check index
The quantitative insulin sensitivity check index (QUICKI) is calculated from the converse of the sum of the logarithms of fasting insulin and fasting glucose levels 22 as follows 1/(log(fasting insulin mU/mL) þ log(fasting glucose mg/dL)).
Statistical analysis
Data for clinical parameters are shown as median and the 25th and 75th percentiles for age, BMI, body weight, waist and hip circumferences, and waist-to-hip ratio. Data of gene expressions and adipocyte morphometry are shown as mean AE standard deviation (SD). Comparisons between obese and non-obese groups as well as between subcutaneous and visceral adipose tissues were performed by independent t-test. Comparisons among different gene expressions were analyzed by one-way analysis of variance followed by Fisher's least significant difference post hoc test. Correlation coefficient calculation was done by using the two-tailed Pearson productmoment correlation method for normally distributed data and using Spearman's Rho method for non-normally distributed data. Each multivariate linear regression model was built by stepwise analysis, incorporating the variables that showed significant correlations. The existence of high co-linearity among variables included in the study was ruled out. A P value less than 0.05 was set as statistical significance.
Results
Clinical characteristics of participants
Clinical characteristics of participants are shown as median and the 25th and 75th percentiles in Table 2 . Plasma glucose, plasma insulin, and QUICKI were revealed in a previous publication showing that QUICKI was higher in non-obese compared with obese humans but plasma Table 2 . Distribution of subjects' age, BMI, body weight, waist and hip circumference, and waist-to-hip ratio of obese and nonobese groups.
Clinical parameters
Obese subjects (n 5 20)
Non-obese subjects (n 5 13) glucose and insulin levels were not different between obese and non-obese groups. 23 mRNA expressions in adipose tissue Y5R mRNA expression was greater in the obese group than in the non-obese group (P < 0.05) in subcutaneous and visceral adipose tissues (Figure 1(a) ). Y5R expression was comparable between subcutaneous and visceral fat in obese and non-obese subjects (Figure 1(b) ). In obese subjects, Y1R showed the highest expression and was significantly higher than Y5R, Y2R, and NPY in both subcutaneous and visceral fat (Figure 1 (c) and (d), all P < 0.05). Y5R expression was significantly higher than Y2R and NPY in visceral fat but not in subcutaneous fat (Figure 1 (d), all P < 0.05). In the non-obese group, Y1R was highest expressed and significantly higher than Y5R, Y2R, and NPY in subcutaneous fat (Figure 1 (e), all P < 0.01)
but it was comparable with other genes in visceral fat ( Figure 1(f) ).
Morphology of subcutaneous and visceral adipose tissues
H&E staining showed the morphology of subcutaneous (Figure 2(a) ) and visceral (Figure 2(b) ) adipose tissues. Subcutaneous adipocytes had larger size than visceral adipocytes.
Adipocyte morphometry
Width and perimeter of subcutaneous adipocytes of the obese were larger than those of the non-obese group (both P < 0.05, Figure 2 (c)). Parameters of visceral adipocytes were significantly higher in the obese than in the non-obese group (all P < 0.01, Figure 2(d) ). Parameters of subcutaneous adipocytes were larger than those of visceral adipocytes in , and Y5R mRNA expression levels in subcutaneous and visceral adipose tissues, respectively, of obese subjects. Panels (e) and (f) show comparisons among NPY, Y1R, Y2R, and Y5R mRNA expression in subcutaneous and visceral adipose tissues, respectively, of non-obese subjects. *P < 0.05, **P < 0.01, ***P < 0.001, compared between groups.
Chatree et al. Adipose Y5R in obese and non-obese humans 789 obese (Figure 2(e) ) and non-obese subjects (Figure 2 (f), all P < 0.05).
Correlations between factors
Correlations between two factors are shown in Table 3 . The correlation coefficient of 0-0.29 was classified as negligible correlation, 0.3-0.49 as low correlation, 0.5-0.69 as moderate correlation, 0.7-0.89 as high correlation, and 0.9-1 as very high correlation. 24 Age showed positive correlations with area, width, and perimeter of visceral adipocytes (low correlations). Body weight was positively correlated with all parameters of subcutaneous (low to moderate correlations) and visceral (high correlations) adipocytes. Height was positively correlated with area, width, and perimeter of subcutaneous adipocytes (moderate correlations) and with all parameters of visceral adipocytes (low correlations). Waist circumference was positively correlated with all parameters in visceral (moderate to high correlations) and subcutaneous (low to moderate correlations) adipocytes. Hip circumference showed positive correlations with all parameters of visceral (moderate to high correlations) and subcutaneous adipocytes (low to moderate correlations). Waist-to-hip ratio was positively correlated with area, width, and perimeter of subcutaneous adipocytes (low correlations), and with all parameters of visceral adipocytes (low to moderate correlations). There was a trend of a positive correlation between waist-to-hip ratio and height of subcutaneous adipocytes (low correlation). Moreover, serum NPY levels were positively correlated with waist circumference (low correlation), and with all parameters of visceral adipocytes (low correlations). Visceral Y1R expression showed a trend of a positive correlation with width of visceral adipocytes (low correlation). Subcutaneous Y2R expression showed a trend of negative (d) show area, width, height, and perimeter of subcutaneous and visceral adipocytes, respectively, compared between obese and non-obese groups. Panels (e) and (f) show area, width, height, and perimeter of adipocytes in obese and nonobese subjects, respectively, compared between subcutaneous and visceral adipocytes. *P < 0.05, **P < 0.01, ***P < 0.001, compared between groups. (A color version of this figure is available in the online journal.) ....................................................................................................................................................... ..... 
Multivariate regression analysis
Multivariate regression analysis showed significant associations between gene expressions and clinical parameters (Table 4) . Taking visceral Y1R expression as the dependent variable, a significant interaction was found when visceral Y5R expression was an independent variable (R 2 =0.597, P < 0.001). Subcutaneous Y2R expression set as the dependent variable showed a significant association with visceral Y2R and subcutaneous Y5R expressions (R 2 =0.920, P < 0.001). Setting visceral Y5R expression as the dependent variable, models of significant interactions were observed by using body weight and visceral Y1R expression (R 2 =0.676, P < 0.001) or BMI and visceral Y1R expression (R 2 =0.718, P < 0.001) as independent variables. These two models were independently constructed to avoid colinearity of factors that had highly significant correlations.
Discussion
This study showed that Y5R expression was higher in obese than in non-obese humans by 2.57-fold in subcutaneous and 3.24-fold in visceral fat. Y5R expression in visceral fat showed positive correlations with obesity-related parameters and visceral Y1R. In multiple linear regression analysis, visceral Y5R expression was positively correlated with body weight, BMI, and visceral Y1R expression. Visceral Y1R was positively associated with visceral Y5R and waist circumference. Additionally, Y5R was strongly and positively associated with Y1R in visceral fat. Our results are supported by a previous study in rodents showing that blockage of Y5R decreased body weight and mesenteric adipose tissue weight. 25 These results indicate that the Y5R has a role in increased obesity, especially in visceral adipose tissue. Furthermore, a strong positive correlation between visceral Y5R and visceral Y1R indicated that both Y receptor subtypes might work cooperatively to increase adiposity, particularly in visceral adipose tissue. This is supported by a previous study showing that there was a synergistic interaction between Y1R and Y5R in increasing food intake and body weight.
14 Furthermore, our previous study also found that Y1R in visceral fat was greater in obese than in normal weight humans, and was positively correlated with body weight, BMI, and waist and hip circumferences. 19 Y5R mRNA in visceral fat was negatively correlated with QUICKI, suggesting that visceral Y5R is related to decreased insulin sensitivity. Our result is consistent with a previous study in mice showing that a Y5R antagonist decreased plasma insulin, but not plasma glucose levels, indicating that inhibition of Y5R led to increased insulin sensitivity. 25 The action of Y5R related to decreased insulin sensitivity corresponds with that of Y1R as we previously showed that Y1R was positively correlated with insulin and HOMA-IR. 19 These findings suggest a role of these two receptors in increased obesity and increased insulin resistance or decrease insulin sensitivity.
In obese subjects, Y1R was 2058.9-fold, Y5R was 374.1-fold, and Y2R was 122.2-fold higher than NPY in subcutaneous fat. In visceral adipose tissue of obese subjects, Y1R was 245.8-fold, Y5R was 127.4-fold, and Y2R was 17.0-fold higher than NPY. In non-obese subjects, Y1R was 3645.4-fold, Y5R was 221.1-fold, and Y2R was 70.59-fold higher than NPY in subcutaneous fat. In visceral fat of non-obese subjects, Y1R was 14.62-fold, Y5R was 4.8-fold, and Y2R was 1.9-fold higher than NPY. These results suggest that Y1R and Y5R are dominantly expressed in human adipose tissue, especially in obese subject in both subcutaneous and visceral adipose tissues and in non-obese subjects in subcutaneous adipose tissue. This study showed that serum NPY levels positively correlated with waist circumference and visceral adipocyte morphometry. Our previous study showed that NPY levels were higher in obese than in normal weight subjects. 19 However, NPY is produced from several peripheral tissues including adipose tissue, 6 adrenal medulla, 26 sympathetic ganglia, and tissues receiving dense sympathetic innervations. 27 Visceral Y1R tended to be positively correlated with width of visceral adipocytes. These results indicate that Y1R might be the major receptor subtype that determines NPY's action on increased adiposity. Blockage of Y1R might help improve the condition of obesity. Additionally, blockage of both Y1R and Y5R might help to further decrease obesity. Interestingly, in visceral fat of non-obese subjects, Y1R expression was not as high as that in obese subjects and was not different from Y5R, Y2R, and NPY. These results suggest that Y1R expression was remarkably increased in obese subjects resulting in a significant difference from other receptors.
Adipocyte morphometry showed a greater size in subcutaneous adipocytes than in visceral adipocytes in obese and non-obese subjects. Our results are similar to previous studies showing that the size of subcutaneous adipocytes is larger than that of visceral adipocytes in obese humans. 28 A possible explanation could be that human visceral adipocytes are more sensitive to catecholamine stimulation because of an increase in beta 1-2 adrenoceptors than subcutaneous adipocytes, 29 resulting in a decline in volume and size of adipocytes. 30 Another study reported that subcutaneous adipocytes had higher lipolytic activity than visceral adipocytes in the same amount of cells because of a larger cell volume of subcutaneous adipocytes. 31 However, the rate of lipolysis was significantly correlated to adipocyte size, regardless of either the region of origin or sex. These results indicate that lipolysis might not be the major determining factor of smaller cell size found in visceral adipocytes.
Width and perimeter, but not area and height, of subcutaneous adipocytes, and area, width, height, and perimeter of visceral adipocytes, were greater in obese than in nonobese patients. These results indicated that obese subjects had a larger size of adipocytes than non-obese patients, especially in visceral adipocytes. Our results are consistent with a previous study reporting that the adipocyte volume of abdominal subcutaneous of obese women is larger than that of non-obese women. 32 Our results showed that body weight, waist and hip circumferences, and waist-to-hip ratio were positively correlated with adipocyte morphometry in subcutaneous and visceral fat, with a much higher correlation coefficient observed in visceral fat. Our previous study revealed that visceral, but not subcutaneous, adipocyte parameters were positively correlated with insulin and HOMA-IR. 33 Taken together, obese people might have increased subcutaneous and visceral fat, with a greater increase in visceral fat, leading to increased insulin resistance and risk of metabolic syndrome.
Visceral Y2R mRNA was negatively correlated with width of subcutaneous and visceral adipocytes. These results suggest that Y2R is associated with a decreased adipocyte size. Our results parallel with a finding from our previous study showing that Y2R mRNA in visceral fat was greater in normal weight than in obese subjects. 20 These findings suggest that Y2R expression in adipose tissue in visceral fat might be related to adiposity reduction in humans. However, a previous study in mice showed that NPY activating through Y2R increased fat proliferation and differentiation, 5 and promoted adipogenesis in vitro, 34 resulting in increased body fat accumulation. The contradictory results of Y2R in regulation of obesity might be species-specific. A positive correlation between subcutaneous Y5R and subcutaneous Y2R was observed in our study. However, our previous study showed that Y2R mRNA was higher in normal weight than in obese subjects in visceral, but not subcutaneous fat. 20 The correlation between subcutaneous Y5R and Y2R might not be related to adiposity, but might be related to depot-specific regulation. Depotspecific regulation of gene expression in adipose tissue was supported by our previous studies as there were positive correlations between gene expression of adipokines, including adiponectin, visfatin, omentin, NPY, and Y receptors, in subcutaneous or in visceral of adipose tissue, with no evidence of cross-linking between adipose tissue depots. 23, 33 In multiple linear regression analysis, subcutaneous Y2R showed positive interactions with subcutaneous Y5R and visceral Y2R. The interaction of Y2R mRNA in subcutaneous and visceral fat was not related to adipose depot-specific regulation. However, this interaction might be related to its concordant action on adipose tissue as a previous study showed a high correlation coefficient (R ¼ 0.932) 20 of Y2R between subcutaneous and visceral fat. Age and parameters of visceral adipocytes were positively correlated, indicating that increasing age might be related to increased visceral adiposity. This result is consistent with a previous study showing that visceral fat area was positively correlated with age in sedentary subjects. 35 The increase in visceral adiposity in aging might be due to a reduction in resting metabolic rate and physical activity. 36 This study showed positive correlations between height of the subjects and parameters of subcutaneous and visceral adipocytes, with higher R values in subcutaneous than in visceral adipocytes. However, a previous study showed that height was negatively correlated with subcutaneous and visceral adipose tissue area in Chinese men. 37 This finding indicates that a larger size of adipocyte found in taller people might not be directly related to the size of adipose tissue or an indicator of determining adipose tissue mass.
Conclusion
In conclusion, this study showed that Y5R mRNA was higher in obese than in non-obese subjects and had positive correlations with obesity-related parameters and visceral Y1R gene expression. Y1R and Y5R were the major receptors in subcutaneous and visceral fat. Adipocyte morphometry of obese subjects was larger than that of non-obese subjects. Measurements of subcutaneous adipocytes were greater than those of visceral adipocytes. Visceral adipocytes showed higher correlations with body weight, waist and hip circumferences, and waist-to-hip ratio than subcutaneous adipocytes, suggesting that increased visceral fat mass might be an indicator of an increased risk of metabolic syndrome. Collectively, the data are in agreement with previous results suggesting that Y1R and Y5R in visceral adipose tissue might have a major impact on increased obesity which might be targets of drug development in decreased adiposity. Investigation of specific blocking of Y1R and Y5R, especially in visceral adipose tissue, may reveal strategies for prevention or treatment of obesity.
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